Doxazosin Mesylate Molecular Structure (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 01)
Doxazosin Mesylate
Product Images NDC 68258-6099
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin Mesylate (NDC 68258-6099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Table 1: Summary Of Effectiveness Data In Placebo-controlled Trials (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 02)
This text is a summary of effectiveness data in placebo-controlled trials for the treatment of BPH (benign prostatic hyperplasia). It includes three studies where the effectiveness of Doxazosin mesylate was compared to a placebo. The results are presented through mean values of baseline and change in symptom scores and maximum flow rate. The studies were done with a different number of patients and for a different period of time. The text includes some specific details about the measurements used to assess changes in the patient's condition.*
Graph: Mean Change In Total Symptom Score From Baseline (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 03)
The text appears to be a graph or chart displaying "Mean Change in Total Symptom Score from Baseline" over a period of "Duration of Treatment (Weeks)". Further information or context is not available.*
Graph: Mean Increase In Maximum Urinary Flow Rate (ml/sec) From Baseline (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 04)
This is a tabulated data showing the mean increase in maximum urinary flow rate from baseline at different weeks of treatment with Doxazosin. There was no change in flow rate at week 0, but there was a statistically significant increase in flow rate at weeks 2, 4, 6, 8, 10, 12, and 14, compared to baseline and/or placebo (as indicated by the asterisks). The maximum dose of Doxazosin used was 8 mg.*
Ndc 68258-6099-xx (Ndc 68258 6099 Xx Patheon)
This is a description of Doxazosin Mesylate 1 mg tablets produced by Patheon Puerto Rico, Inc. and includes information such as its product ID, NDC, manufacturer lot number, and pedigree number. The tablets must be kept in tight/light resistant containers and should be taken orally once a day as directed by a physician. It also lists the tablet's warning to keep it out of reach of children and store between 68° - 77° F. Lastly, it displays the drug's packaging information related to its exclusive distribution by DispenseQuick Solitons in Santa Ana, CA.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
